Lorenzo Scalise

Here below are the publications (2) participated by Lorenzo Scalise along with Andrea Rinaldi (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations).

Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma

eJHaem, 27 luglio 2022

2) Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.

American Society of Hematology, https://ashpublications.org/bloodadvances/article/4/5/819/452604/Copanlisib-synergizes-with-conventional-and

Facts & figures

Lorenzo Scalise has coordinated or participated in 2 publications
(as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) whose subjects can be represented by this 5 elements tag cloud:

BET (1) HDAC (1) JAK (1) LRRK2 (1) LYMPHOMAS (1)

Lorenzo Scalise has coordinated or participated in 2 publications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) featured by 2 scientific journals:

American Society of Hematology (1) eJHaem (1)

Lorenzo Scalise has coordinated or participated in 2 publications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) involving also 17 co-authors being active in Ticino:

Filippo Spriano (2) Emanuele Zucca (2) Chiara Tarantelli (2) Anastasios Stathis (2) Luciano Cascione (2) Francesco Bertoni (2) Eugenio Gaudio (2) Andrea Rinaldi (2) Alberto Jesus Arribas (2) Francesco Margheriti (1) Michele Mascia (1) Giulio Sartori (1) Ivo Kwee (1) Davide Rossi (1) Sara Napoli (1) Marilia Barreca (1) Gaetanina Golino (1)

Lorenzo Scalise has coordinated or participated in 2 pubblications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) in whose synopsis the 11 most frequently used terms (excluding 16 not relevant terms) are here listed:

L.S. WORD CLOUD lymphoma (2) copanlisib (1) synergizes (1) venetoclax (1) b (1) t-cell (1) pharmacologic (1) screen (1) combinations (1) bet (1) lrrk (1)

In the synopsis of the whole 3332 pubblications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations), the 197 most frequently used terms (excluding 16 not relevant or unfrequently used terms (terms used less than 10 times) are here listed:

THE WHOLE WORD CLOUD cancer (299) covid- (186) thyroid (111) pet (109) cardiac (107) prostate (107) sars-cov- (103) hiv (89) atrial (81) breast (81) coronary (79) sclerosis (76) fibrillation (69) lymphoma (68) pandemic (67) bone (54) aortic (52) heart (51) artery (51) stroke (50) liver (47) carcinoma (46) brain (44) antibodies (42) cardiovascular (41) lung (40) mri (39) transcatheter (36) metastatic (35) dna (35) ventricular (35) kidney (34) nodules (34) tumor (33) extracellular (33) virus (33) myocardial (32) knee (31) ultrasound (30) oncology (30) mitral (27) antibody (27) esmo (27) percutaneous (26) f-fdg (26) hepatitis (25) vesicles (25) spinal (25) antiplatelet (24) cervical (24) ischemic (24) osteoarthritis (23) tuberculosis (23) diabetes (23) infarction (23) chemotherapy (23) ovarian (22) sentinel (22) radiotherapy (22) bladder (22) pulmonary (22) sperm (22) ehra (22) endovascular (21) implantation (21) transplantation (21) vaccination (21) renal (21) blood (20) lymph (19) resonance (19) plasma (19) tomography (19) urinary (19) bacterial (19) b-cell (18) monoclonal (18) nuclear (18) tumors (18) pacing (18) fdg (17) colorectal (17) laparoscopic (17) mice (17) implantable (16) autoimmune (16) vaccine (16) transplant (16) coronavirus (16) immunodeficiency (16) radiomics (15) membrane (15) preclinical (15) metabolic (15) metabolism (15) vascular (15) musculoskeletal (15) tricuspid (14) endometrial (14) pneumonia (14) antiretroviral (14) biomarker (14) serum (14) mrna (14) metastasis (14) lymphomas (14) fractures (14) peripheral (14) neurocognitive (14) leukemia (14) occlusion (13) male (13) behavior (13) muscle (13) interventions (13) legs (13) radiation (13) arterial (13) hemorrhage (13) nerve (13) biomarkers (13) pregnancy (13) lymphocytic (13) medullary (12) malignant (12) platelet-rich (12) hiv- (12) metastases (12) tau (12) iga (12) conference (12) mutations (12) malignancy (12) brugada (12) joint (12) fna (12) grafts (12) ischemia (12) dementia (12) esc (12) radiology (11) baseline (11) gastric (11) intravenous (11) arrhythmia (11) dynamic (11) incontinence (11) burden (11) pi (11) contemporary (11) contrast-enhanced (11) pathways (11) adherence (11) catheter (11) parkinson (11) limb (11) cytology (11) signaling (11) neck (11) mesenchymal (11) senescence (11) lockdown (11) il- (11) administration (10) overview (10) regurgitation (10) depression (10) art (10) idiopathic (10) clonal (10) bayesian (10) checkpoint (10) antithrombotic (10) precision (10) recovery (10) possible (10) prognosis (10) cancers (10) vascularized (10) adapted (10) peptide (10) ecg (10) infectious (10) fixation (10) prolapse (10) pci (10) hip (10) migraine (10) skin (10) prophylaxis (10) follicular (10) igg (10) vitamin (10) epidemiology (10) lipid (10) refractory (10) anesthesia (10)

Il mondo delle startup

Lorenzo Scalise has participated - as a whole - in 2 publications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) - here below are the ones participated along with Andrea Rinaldi

1) Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma

2) Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.

Lorenzo Scalise has participated - as a whole - in 2 publications
(as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) - here below are the ones participated along with Andrea Rinaldi